Biotech companies have brought many important treatments to market, from ones that address rare diseases to ones that handle ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 5 years by 5.11% on an annualized basis producing an ...

Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.27%.

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.00% to $475.08 Wednesday, on what proved to be an all-around rough trading ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Vertex Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations ...

Vertex Pharmaceuticals (NASDAQ:VRTX ... an increase of $100 million from previous projections. The company's stock has shown resilience, with a year-to-date performance of +22% as of September 2024.